modelH01CB03
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Lanreotide | |
| ATC code: | H01CB03 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 120 | mg |
| volume of distribution: | 18 | L |
| clearance: | 23.5 | l/h |
| other parameters in model implementation | ||
Lanreotide is a long-acting somatostatin analog used in the treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors, and symptoms associated with carcinoid syndrome. It is typically administered as a deep subcutaneous or intramuscular injection. Lanreotide is approved for use in many countries and is a clinically used drug.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult subjects and patients with acromegaly after single deep subcutaneous injection.
References
Buil-Bruna, N, et al., & Trocóniz, IF (2016). Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials. Clinical pharmacokinetics 55(4) 461–473. DOI:10.1007/s40262-015-0329-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26416534
Trocóniz, IF, et al., & Obach, R (2009). Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months. Clinical pharmacokinetics 48(1) 51–62. DOI:10.2165/0003088-200948010-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19071884
Yang, LP, & Keating, GM (2010). Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 70(13) 1745–1769. DOI:10.2165/11204510-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20731479
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)